Exagen Inc. XGN
Set alert
At close · Oct 30
After hours · Oct 30, 4:00 PM ET
- YTD
- +41.28%
- 1 year
- -26.96%
- Open
- 8.58
- Prev close
- 8.70
- Mkt cap
- 208.10M
- Vol
- 394.01K
- Avg vol
- 370.26K
- EPS
- -0.81
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 8.28
- High
- 8.61
- Forward P/E
- -5.96
- Beta
- 1.35
- Short ratio
- 3.12
- Inst. own
- 57.22%
- Dividend
- 0.00
- Ex-div date
- Earnings
- Aug 5, 2024
- 50-d avg
- 3.59
- 200-d avg
- 2.50
- 1y target
- 6.25
News
3 days ago globenewswire.com
Exagen Inc. to Participate in Upcoming Investor Conferences
Exagen will participate in the Canaccord Genuity MedTech & Diagnostics Conference November 11 and the Craig-Hallum Alpha Select Conference November 17
5 days ago globenewswire.com
Exagen to Announce Third Quarter Financial Results on November 10, 2026
CARLSBAD, Calif., Oct. 27, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended September 30,…
1 week ago defenseworld.net
Exagen (NASDAQ: XGN) owner buys 14,000 shares in new insider filing
What happened Exagen Inc. (NASDAQ: XGN) filed a Form 4 showing Jorey Chernett, a director and 10% owner, bought 14,000 common shares on 2026-10-19. The filing lists the trade as a purchase, and the…
1 week ago defenseworld.net
Exagen (NASDAQ:XGN) CEO John Aballi Sells 34,294 Shares of Stock
Exagen Inc. (NASDAQ: XGN - Get Free Report) CEO John Aballi sold 34,294 shares of the company's stock in a transaction on Friday, October 16th. The stock was sold at an average price of $7.87, for a…
-
1 week ago benzinga.com
Canaccord Genuity Maintains Buy on Exagen, Raises Price Target to $11
Canaccord Genuity analyst Kyle Mikson maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $9 to $11.
-
2 weeks ago benzinga.com
TD Cowen Maintains Buy on Exagen, Raises Price Target to $11
TD Cowen analyst Dan Bergstrom maintains Exagen (NASDAQ:XGN) with a Buy and raises the price target from $10 to $11.
1 month ago defenseworld.net
Universal Health Services (NYSE:UHS) versus Exagen (NASDAQ:XGN) Financial Analysis
Universal Health Services (NYSE: UHS - Get Free Report) and Exagen (NASDAQ: XGN - Get Free Report) are both healthcare companies, but which is the superior investment? We will contrast the two…
1 month ago defenseworld.net
Exagen Inc. (NASDAQ:XGN) Receives Consensus Recommendation of “Moderate Buy” from Analysts
Exagen Inc. (NASDAQ: XGN - Get Free Report) has earned an average rating of "Moderate Buy" from the nine analysts that are currently covering the company, MarketBeat Ratings reports. One research…
1 month ago defenseworld.net
InfuSystem (NYSE:INFU) & Exagen (NASDAQ:XGN) Head to Head Contrast
Exagen (NASDAQ: XGN - Get Free Report) and InfuSystem (NYSE: INFU - Get Free Report) are both small-cap healthcare companies, but which is the superior business? We will compare the two companies…
1 month ago defenseworld.net
Exagen (NASDAQ:XGN) versus Gaxos.ai (NASDAQ:GXAI) Financial Review
Exagen (NASDAQ: XGN - Get Free Report) and Gaxos.ai (NASDAQ: GXAI - Get Free Report) are both small-cap healthcare companies, but which is the better business? We will compare the two businesses…
2 months ago defenseworld.net
Exagen Inc. (NASDAQ:XGN) Given Average Rating of “Moderate Buy” by Brokerages
Shares of Exagen Inc. (NASDAQ: XGN - Get Free Report) have been assigned an average rating of "Moderate Buy" from the nine analysts that are currently covering the company, MarketBeat reports. One…
2 months ago defenseworld.net
Reviewing Amplifon (OTCMKTS:AMFPF) & Exagen (NASDAQ:XGN)
Amplifon (OTCMKTS:AMFPF - Get Free Report) and Exagen (NASDAQ: XGN - Get Free Report) are both healthcare companies, but which is the better stock? We will contrast the two businesses based on the…
2 months ago marketbeat.com
Exagen Q2 Earnings Call Highlights
Exagen NASDAQ: XGN reported record second-quarter revenue as growth in AVISE CTD test volume, average selling price and Pharma Services revenue brought the autoimmune diagnostics company close to…
2 months ago seekingalpha.com
Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript
Exagen Inc. (XGN) Q2 2026 Earnings Call Transcript
2 months ago zacks.com
Exagen Inc. (XGN) Reports Q2 Loss, Beats Revenue Estimates
Exagen Inc. (XGN) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.19. This compares to a loss of $0.18 per share a year ago.
2 months ago globenewswire.com
Exagen Inc. Reports Second Quarter 2026 Financial Results
Achieved record total revenue, test volume and trailing twelve-month ASP Reduced net loss by nearly 30% and narrowed adjusted EBITDA loss to $0.1 million Increased full-year revenue guidance to $72 -…
3 months ago globenewswire.com
Exagen Inc. to Participate in Upcoming Investor Conference
CARLSBAD, Calif., July 28, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of autoimmune testing, today announced that management will participate in the following investor…
3 months ago globenewswire.com
Exagen to Announce Second Quarter Financial Results on August 4, 2026
CARLSBAD, Calif., July 21, 2026 (GLOBE NEWSWIRE) -- Exagen Inc. (Nasdaq: XGN), a leading provider of innovative autoimmune testing, will release financial results for the quarter ended June 30, 2026,…
5 months ago globenewswire.com
Exagen Announces Publication of Systematic Review Confirming Robust Real-World Performance of AVISE Lupus
Uniquely identified ~25% of the SLE patients who would otherwise be missed by conventional markers Demonstrated superior diagnostic accuracy compared with conventional testing, supporting earlier,…
5 months ago zacks.com
How Much Upside is Left in Exagen (XGN)? Wall Street Analysts Think 73.05%
The average of price targets set by Wall Street analysts indicates a potential upside of 73.1% in Exagen (XGN). While the effectiveness of this highly sought-after metric is questionable, the…
5 months ago seekingalpha.com
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
Exagen Inc. (XGN) Q1 2026 Earnings Call Transcript
5 months ago marketbeat.com
Exagen Q1 Earnings Call Highlights
Exagen NASDAQ: XGN reported record first-quarter revenue and reaffirmed its full-year outlook, as executives said growth in testing volume, improved reimbursement execution and expanding clinician…